chloroorienticin-a has been researched along with Bacteremia* in 2 studies
2 other study(ies) available for chloroorienticin-a and Bacteremia
| Article | Year |
|---|---|
Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.
Gram-positive pathogens (n = 525) isolated from bloodstream infections were tested by a reference broth microdilution method to establish antibiotic susceptibility trends (1985 to 1991). Cefazolin, ciprofloxacin, gentamicin, novobiocin, oxacillin, rifampin, teicoplanin, vancomycin, trimethoprim/sulfamethoxazole, daptomycin and two investigational glycopeptides (LY264826 and MDL62873) were investigated. Strains were selected without bias (first two isolates each month/species; no patient duplicates) as follows: 132 Staphylococcus aureus, 129 Staphylococcus epidermidis, 72 Staphylococcus haemolyticus, 130 Enterococcus faecalis and 62 other enterococci. All isolates were susceptible to vancomycin and teicoplanin except for Staphylococcus haemolyticus which had a resistant teicoplanin MIC90 of 64 micrograms/mL. The susceptibilities to vancomycin and teicoplanin were unchanged over the monitored period. Daptomycin, LY264826 and MDL62873 also demonstrated consistent activity; MDL62873 being superior with a MIC90 of 0.12 micrograms/mL. In 1990-1991 a significantly increased resistance to ciprofloxacin was observed among oxacillin-resistant strains of staphylococci. Our data suggest that the emergence of invasive vancomycin-resistant strains in Gram-positive isolates remains a rare phenomenon. However, we have experienced an emergence of numerous ciprofloxacin-resistant strains among staphylococci that precludes its empirical use at our institution. Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Hospitals, University; Humans; Lactams; Microbial Sensitivity Tests; Ristocetin; Staphylococcus; Time Factors; Vancomycin | 1993 |
Comparison of LY264826-gentamicin with vancomycin-gentamicin against enterococci from blood cultures.
The combination of the new glycopeptide LY264826 and gentamicin was compared with the combination of vancomycin and gentamicin against 30 strains of enterococci, comprising 20 strains of Enterococcus faecalis, five strains of Enterococcus faecium and five strains of Enterococcus avium, isolated from blood cultures. LY264826 plus gentamicin was synergic against E. faecalis and E. faecium, but not against E. avium. Topics: Anti-Bacterial Agents; Bacteremia; Drug Synergism; Drug Therapy, Combination; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Gentamicins; Humans; Microbial Sensitivity Tests; Vancomycin | 1992 |